olivLaw · European equity research
Hampiðjan hf HAMP.IC
Iceland · Nasdaq Iceland · ISIN IS0000000305 · Vertical: Listed companies from Iceland
At the close of 05 Nov 2026, Hampiðjan hf (HAMP.IC) stock was 79.00 ISK (+0.00% on the day), with beta 0.32, 52-week range 79.00–119.00 ISK.
Data as of · Source: ESEF annual reports and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 29.3
- oversold (≤ 30)
- Bollinger (20, 2)
- 78.76 – 85.89
- in the lower half of the band · %B 0.03 · band width 8.7%
- SMA 50 / 200
- 85.41 / 93.72
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -1.55 / -1.33
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | EURO STOXX 50 | vs EURO STOXX 50 | Vertical median | |
|---|---|---|---|---|
| 1 month | −8.1% | +0.4% | −8.5 pp | — |
| 3 months | −10.2% | −3.3% | −7.0 pp | — |
| 6 months | −11.7% | +4.0% | −15.7 pp | — |
| Year to date | −22.5% | +8.1% | −30.6 pp | — |
| 1 year | −31.9% | +10.7% | −42.6 pp | −6.8% |
| 3 years | −37.3% | +50.1% | −87.4 pp | +17.9% |
| 5 years | unavailable | +43.6% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
the price (USD) and the reports are in different currencies
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 322.1 m | 311.0 m | 359.7 m |
| Revenue YoY | unavailable | −3.5% | +15.7% |
| Net income | 10.4 m | 12.9 m | 4.3 m |
| Net income YoY | unavailable | +24.2% | −66.6% |
| Diluted EPS | 2.02 | 2.24 | unavailable |
| Diluted EPS YoY | unavailable | +10.9% | unavailable |
| net % | 3.2% | 4.2% | 1.2% |
| Free cash flow | unavailable | unavailable | unavailable |
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 26.4 m EUR
- Financial debt
- 211.4 m EUR
- Net debt
- 185.0 m EUR
- Equity
- 270.3 m EUR
- Total assets
- 547.5 m EUR
- Debt / equity
- 0.78x
- Current ratio
- 1.85x
- ROE
- 1.6%
- ROA
- 0.8%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (EUR)
Margins
Income statement · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Revenue | 322.1 m | 311.0 m | 359.7 m | esef· 10 Mar 2026verified |
| Cost of revenue | 235.3 m | 226.9 m | 263.0 m | esef· 10 Mar 2026verified |
| Gross profit | 86.8 m | 84.1 m | 96.7 m | esef· 10 Mar 2026verified |
| Operating income | 23.5 m | 23.6 m | 24.3 m | esef· 10 Mar 2026verified |
| Interest expense | 13.5 m | 13.5 m | 12.7 m | esef· 10 Mar 2026verified |
| Pre-tax income | 15.1 m | 17.2 m | 11.3 m | esef· 10 Mar 2026verified |
| Income tax | 3.4 m | 2.9 m | 2.5 m | esef· 10 Mar 2026verified |
| Net income | 10.4 m | 12.9 m | 4.3 m | esef· 10 Mar 2026verified |
| Diluted EPS | 2.02 | 2.24 | — | esef· 11 Mar 2025verified |
| Dividend per share | 1.63 | 1,100.00 | 1,100.00 | esef· 10 Mar 2026verified |
Balance sheet · EUR
| Line | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|
| Cash | 53.0 m | 41.4 m | 26.4 m | esef· 10 Mar 2026verified |
| Receivables | 59.2 m | 66.6 m | 71.9 m | esef· 10 Mar 2026verified |
| Inventories | 125.8 m | 126.7 m | 138.4 m | esef· 10 Mar 2026verified |
| Current assets | 238.0 m | 234.8 m | 237.2 m | esef· 10 Mar 2026verified |
| Property, plant & equipment, net | 169.6 m | 180.7 m | 194.1 m | esef· 10 Mar 2026verified |
| Intangibles (excl. goodwill) | 76.9 m | 86.6 m | 105.1 m | esef· 10 Mar 2026verified |
| Total assets | 490.0 m | 509.5 m | 547.5 m | esef· 10 Mar 2026verified |
| Accounts payable | 41.2 m | 46.7 m | 56.4 m | esef· 10 Mar 2026verified |
| Short-term debt | 47.9 m | 51.0 m | 70.4 m | esef· 10 Mar 2026verified |
| Long-term debt | 120.2 m | 127.6 m | 141.0 m | esef· 10 Mar 2026verified |
| Current liabilities | 92.3 m | 100.8 m | 128.6 m | esef· 10 Mar 2026verified |
| Total liabilities | 219.7 m | 236.3 m | 277.2 m | esef· 10 Mar 2026verified |
| Equity | 270.3 m | 273.2 m | 270.3 m | esef· 10 Mar 2026verified |
| Shares outstanding at year end | 5.2 m | 5.8 m | — | esef· 10 Mar 2026derived |
Cash flow · EUR
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 4 of at least 6
- score weight coverage: 27.1% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
05 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Price and reporting are in different currencies; market indicators are unavailable.
Key indicators
Coverage and freshness
Score by group
27% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 12.96 – 20,400.00 EUR.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (EUR per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDAunavailable · input data missing
- Peers: P/E12.96 – 15.38 (Mid 13.02)5 companies used · median multiple 17.4x · quartiles 17.3x – 20.5xASAR.IC, BERA.IC, FESTI.IC, HAGA.IC, NOVA.IC
- Dividend discount (DDM)14,960.00 – 20,400.00 (Mid 17,261.54)
Assumptions (illustrative, editorial)
- Risk-free rate
- 3.0%
- Equity risk premium
- 5.5%
- Beta (default)
- 1.00
- Cost of equity
- 8.5%
- Terminal growth
- 2.0%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 4.4% | 14 (vs peers) | 38% |
| Net margin · Quality | 1.2% | 11 (vs peers) | 23% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 1.9x | 6 (on a fixed band) | 23% |
| Current ratio · Balance sheet | 1.8x | 87 (on a fixed band) | 15% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet39/100 · 2/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality13/100 · 2/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Hampiðjan hf (HAMP.IC). Latest full fiscal year: 2025; data up to 2025-12-31.
Figures computed from the financial statements: revenue 359.7 m EUR in 2025; YoY growth 15.7%; net margin 1.2%; ROE 1.7%.
The estimated value range is 7,486.48–10,207.69 EUR per share (median of 2 methods, agreement: low); assumptions are illustrative. The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (indicators available: 4 of at least 6; score weight coverage: 27.1% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 1.8x
What contradicts it
- ROIC: 4.4%
- Net margin: 1.2%
- Interest coverage: 1.9x
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Listed companies from Iceland · same country · compared with 10 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| HAGA.ICHagar hf. | 133.6 bn | 20.5 | 18.2% | 3.8% | +9.3% | +8% / +83% |
| FESTI.ICFesti hf. | 90.9 bn | 22.8 | 10.1% | 2.6% | +13.4% | −8% / +67% |
| HEIMAR.ICHeimar hf. | 61.3 bn | 7.5 | 13.5% | 55.5% | +7.7% | −6% / +49% |
| BERA.ICÖlgerðin Egill Skallagríms hf. | 37.1 bn | 17.3 | 13.7% | 5.9% | +7.7% | −24% / +0% |
| NOVA.ICNova Klúbburinn hf | 12.0 bn | 14.8 | 8.5% | 6.1% | +2.8% | −26% / −16% |
| ALVO.ICAlvotech | — | — | — | 9.0% | +43.4% | −14% / −58% |
| ASAR.ICSíminn hf. | — | 17.4 | — | — | +3.0% | −19% / +27% |
| BRIM.ICBrim hf. | — | — | 11.9% | 14.6% | +5.2% | +19% / +13% |
| EIK.ICEik Fasteignafélag Hf. | — | — | 10.2% | 43.6% | +9.5% | +1% / +23% |
| EIM.ICEimskipafélag Íslands hf. | — | — | 3.2% | 1.2% | −4.7% | +6% / −35% |
| HAMP.ICHampiðjan hf | — | — | 1.7% | 1.2% | +15.7% | −26% / −37% |
1- and 3-year price returns: for HAMP.IC from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
The qualitative analysis has not been written for this company yet.
Products, market & competition
The qualitative analysis has not been written for this company yet.
News & filings
In the press
No news in our archive over the last 180 days.
Annual reports (ESEF)
- Annual report 202510 Mar 2026
- Annual report 202411 Mar 2025
Figures computed by olivLaw from ESEF annual reports and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.